



PRESS RELEASE

Three in four adults globally say they'd get a vaccine for COVID -19

Most do not expect any will be available before the end of year; fear of side effects is top reason for not wanting to take the vaccine

New York, NY, September 1, 2020 — In a new Ipsos survey of nearly 20,000 adults from 27 countries on behalf of the World Economic Forum, 74% say they would get a vaccine for COVID-19 if it were available. However, 59% do not expect this will be an option before the end of this year. The reason most commonly given by those who would not get a vaccine is worry about side effects (56%) followed by doubt about its effectiveness (29%).

Intentions to get vaccinated against COVID-19

Globally, 74% of all adults surveyed agree that, "if a vaccine for COVID-19 were available, I would get it". However, only 37% *strongly* agree while 37% *somewhat* agree. Overall, 26% disagree (15% *somewhat* disagree and 12% *strongly* disagree).


In most countries, those who agree outnumber those who disagree by a significant margin (more than 50 percentage points in 12 out of 27 countries).

- The countries where Covid-19 vaccination intent is highest are: China (97%), Brazil (88%), Australia (88%), and India (87%)
- Those where it is lowest are: Russia (54%), Poland (56%), Hungary (56%), and France (59%).



PRESS RELEASE

If a vaccine for COVID-19 were available, I would get it



Expectation that a COVID-19 will be available this year


Across all 27 countries, 59% *disagree* that “a vaccine for COVID-19 will be available to me before the end of 2020” (23% strongly and 36% somewhat) while the other 41% agree (9% strongly and 31% somewhat).

- Again, China stands out for its optimism, with 87% of those surveyed expecting a vaccine will be ready this year. Agreement is also high in Saudi Arabia (75%) and India (74%).
- By contrast, skepticism prevails in Germany, Belgium, Japan, and Poland where fewer than one in four adults anticipate that a vaccine will be available at some point in the next four months.



PRESS RELEASE

A vaccine for COVID-19 will be available to me before the end of 2020



Reasons for not taking a vaccine

The nearly 5,000 adults surveyed who do not intend to take a vaccine for COVID-19 were asked why they would not do so. In every one of the 27 countries, the #1 reason is worry about the side effects, cited by 56% globally (from 70% in Spain and 68% in Sweden to 41% in Argentina and 40% in Saudi Arabia).

The second-most common reason for not wanting to take a COVID-19 vaccine is doubt about its effectiveness, cited by 29% globally (from as many as 44% in Russia and Poland to just 12% in China and 9% in Mexico).


The third most common reason is the perception of not being enough at risk from COVID-19, cited by 19% globally. Among those who are reluctant to be vaccinated, this view is most prevalent in India (37%), Malaysia (36%) and Sweden (35%), while it is least so in Italy (7%) and Brazil (10%).

General opposition to vaccines is cited by 17% of those who would not get a COVID-19 vaccine globally, but as many as 30% in Russia and Italy.



PRESS RELEASE

Reasons for not taking a vaccine





PRESS RELEASE

About the Study

These are the results of a survey conducted by Ipsos between July 24 and August 7, 2020 on its Global Advisor online survey platform among a total of 19,519 adults, aged 18-74 in United States, Canada, Malaysia, South Africa, and Turkey, and aged 16-74 in 22 other countries.

The sample consists of approximately 1,000 individuals in each of Australia, Belgium, Brazil, Canada, China (mainland), France, Germany, Great Britain, Italy, Japan, Spain, and the U.S., and 500 individuals in each of Argentina, Chile, Hungary, India, Malaysia, Mexico, the Netherlands, Peru, Poland, Russia, Saudi Arabia, South Africa, South Korea, Sweden, and Turkey.

The samples in Argentina, Australia, Belgium, Canada, France, Germany, Great Britain, Hungary, Italy, Japan, the Netherlands, Poland, South Korea, Spain, Sweden, and the U.S. can be taken as representative of these countries' general adult population under the age of 75. The samples in Brazil, Chile, China (mainland), India, Malaysia, Mexico, Peru, Russia, Saudi Arabia, South Africa and Turkey are more urban, more educated, and/or more affluent than the general population. The survey results for these countries should be viewed as reflecting the views of the more "connected" segment of these population.

The data is weighted so that each country's sample composition best reflects the demographic profile of the adult population according to the most recent census data.

Where results do not sum to 100 or the 'difference' appears to be +/-1 more/less than the actual, this may be due to rounding, multiple responses or the exclusion of don't knows or not stated responses.

The precision of Ipsos online polls are calculated using a credibility interval with a poll of 1,000 accurate to +/- 3.5 percentage points and of 500 accurate to +/- 4.8 percentage points. For more information on the Ipsos use of credibility intervals, please visit the Ipsos website.

The publication of these findings abides by local rules and regulations.

For more information on this news release, please contact:

Nicolas Boyon
Senior Vice President, Public Affairs, U.S.
+1 646 309 4879
nicolas.boyon@ipsos.com

Kate Silverstein
Media Relations Specialist, Public Affairs, U.S.
+1 718 755 8829
kate.silverstein@ipsos.com



PRESS RELEASE

About Ipsos

Ipsos is the world's third largest market research company, present in 90 markets and employing more than 18,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. We serve more than 5000 clients across the world with 75 business solutions.

Founded in France in 1975, Ipsos is listed on the Euronext Paris since July 1st, 1999. The company is part of the SBF 120 and the Mid-60 index and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com